Anavex ‘Cautiously Optimistic’ After Noting Cognitive Improvement in Alzheimer’s Treatment

Anavex ‘Cautiously Optimistic’ After Noting Cognitive Improvement in Alzheimer’s Treatment
Anavex Life Sciences says its Alzheimer’s drug candidate Anavex 2-73 may have a role in treating the disease. Data from a long-term extension trial, although small, indicated that the therapy improved cognitive and functional measures in patients. According to data presented during the recent 10th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting in Boston, the most

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Robert Jacklin says:

    This is the first time I’ve ever read an article on a AD trial that over a 57 week trial a well tolerated oral drug has IMPROVED cognition! Looks like Anavex has discovered the right target.

Leave a Comment

Your email address will not be published. Required fields are marked *